Literature DB >> 23075516

Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase.

Mathieu Métifiot1, Kasthuraiah Maddali, Barry C Johnson, Stephen Hare, Steven J Smith, Xue Zhi Zhao, Christophe Marchand, Terrence R Burke, Stephen H Hughes, Peter Cherepanov, Yves Pommier.   

Abstract

On the basis of a series of lactam and phthalimide derivatives that inhibit HIV-1 integrase, we developed a new molecule, XZ-259, with biochemical and antiviral activities comparable to raltegravir. We determined the crystal structures of XZ-259 and four other derivatives in complex with the prototype foamy virus intasome. The compounds bind at the integrase-Mg(2+)-DNA interface of the integrase active site. In biochemical and antiviral assays, XZ-259 inhibits raltegravir-resistant HIV-1 integrases harboring the Y143R mutation. Molecular modeling is also presented suggesting that XZ-259 can bind in the HIV-1 intasome with its dimethyl sulfonamide group adopting two opposite orientations. Molecular dynamics analyses of the HIV-1 intasome highlight the importance of the viral DNA in drug potency.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23075516      PMCID: PMC3548936          DOI: 10.1021/cb300471n

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  24 in total

1.  Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.

Authors:  Stephen Hare; Ann M Vos; Reginald F Clayton; Jan W Thuring; Maxwell D Cummings; Peter Cherepanov
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-28       Impact factor: 11.205

2.  MK-0536 inhibits HIV-1 integrases resistant to raltegravir.

Authors:  Mathieu Métifiot; Barry Johnson; Steven Smith; Xue Zhi Zhao; Christophe Marchand; Terrence Burke; Stephen Hughes; Yves Pommier
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

Review 3.  Integrase inhibitors to treat HIV/AIDS.

Authors:  Yves Pommier; Allison A Johnson; Christophe Marchand
Journal:  Nat Rev Drug Discov       Date:  2005-03       Impact factor: 84.694

4.  Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).

Authors:  Stephen Hare; Steven J Smith; Mathieu Métifiot; Albert Jaxa-Chamiec; Yves Pommier; Stephen H Hughes; Peter Cherepanov
Journal:  Mol Pharmacol       Date:  2011-06-30       Impact factor: 4.436

5.  Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.

Authors:  Mathieu Métifiot; Nick Vandegraaff; Kasthuraiah Maddali; Alena Naumova; Xuemin Zhang; David Rhodes; Christophe Marchand; Yves Pommier
Journal:  AIDS       Date:  2011-06-01       Impact factor: 4.177

6.  Retroviral intasome assembly and inhibition of DNA strand transfer.

Authors:  Stephen Hare; Saumya Shree Gupta; Eugene Valkov; Alan Engelman; Peter Cherepanov
Journal:  Nature       Date:  2010-01-31       Impact factor: 49.962

7.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.

Authors:  Vincenzo Summa; Alessia Petrocchi; Fabio Bonelli; Benedetta Crescenzi; Monica Donghi; Marco Ferrara; Fabrizio Fiore; Cristina Gardelli; Odalys Gonzalez Paz; Daria J Hazuda; Philip Jones; Olaf Kinzel; Ralph Laufer; Edith Monteagudo; Ester Muraglia; Emanuela Nizi; Federica Orvieto; Paola Pace; Giovanna Pescatore; Rita Scarpelli; Kara Stillmock; Marc V Witmer; Michael Rowley
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

8.  Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.

Authors:  Signe Fransen; Soumi Gupta; Robert Danovich; Daria Hazuda; Michael Miller; Marc Witmer; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

9.  The mechanism of retroviral integration from X-ray structures of its key intermediates.

Authors:  Goedele N Maertens; Stephen Hare; Peter Cherepanov
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

10.  3'-processing and strand transfer catalysed by retroviral integrase in crystallo.

Authors:  Stephen Hare; Goedele N Maertens; Peter Cherepanov
Journal:  EMBO J       Date:  2012-05-11       Impact factor: 11.598

View more
  21 in total

Review 1.  HIV integrase inhibitors: 20-year landmark and challenges.

Authors:  Mathieu Métifiot; Christophe Marchand; Yves Pommier
Journal:  Adv Pharmacol       Date:  2013

Review 2.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

3.  Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain.

Authors:  Giuliana Cuzzucoli Crucitti; Mathieu Métifiot; Luca Pescatori; Antonella Messore; Valentina Noemi Madia; Giovanni Pupo; Francesco Saccoliti; Luigi Scipione; Silvano Tortorella; Francesca Esposito; Angela Corona; Marta Cadeddu; Christophe Marchand; Yves Pommier; Enzo Tramontano; Roberta Costi; Roberto Di Santo
Journal:  J Med Chem       Date:  2015-02-11       Impact factor: 7.446

4.  N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase.

Authors:  Luca Pescatori; Mathieu Métifiot; Suhman Chung; Takashi Masoaka; Giuliana Cuzzucoli Crucitti; Antonella Messore; Giovanni Pupo; Valentina Noemi Madia; Francesco Saccoliti; Luigi Scipione; Silvano Tortorella; Francesco Saverio Di Leva; Sandro Cosconati; Luciana Marinelli; Ettore Novellino; Stuart F J Le Grice; Yves Pommier; Christophe Marchand; Roberta Costi; Roberto Di Santo
Journal:  J Med Chem       Date:  2015-05-26       Impact factor: 7.446

5.  Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.

Authors:  Mathieu Métifiot; Barry C Johnson; Evgeny Kiselev; Laura Marler; Xue Zhi Zhao; Terrence R Burke; Christophe Marchand; Stephen H Hughes; Yves Pommier
Journal:  Nucleic Acids Res       Date:  2016-07-01       Impact factor: 16.971

Review 6.  Blind prediction of HIV integrase binding from the SAMPL4 challenge.

Authors:  David L Mobley; Shuai Liu; Nathan M Lim; Karisa L Wymer; Alexander L Perryman; Stefano Forli; Nanjie Deng; Justin Su; Kim Branson; Arthur J Olson
Journal:  J Comput Aided Mol Des       Date:  2014-03-05       Impact factor: 3.686

Review 7.  6,7-Dihydroxyisoindolin-1-one and 7,8-Dihydroxy-3,4-Dihydroisoquinolin- 1(2H)-one Based HIV-1 Integrase Inhibitors.

Authors:  Xue Zhi Zhao; Mathieu Metifiot; Steven J Smith; Kasthuraiah Maddali; Christophe Marchand; Stephen H Hughes; Yves Pommier; Terrence R Burke
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

8.  Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition.

Authors:  Murugesan Vanangamudi; Pramod C Nair; S E Maida Engels; Senthilkumar Palaniappan; Vigneshwaran Namasivayam
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Influence of Drug Resistance Mutations on the Activity of HIV-1 Subtypes A and B Integrases: a Comparative Study.

Authors:  O A Shadrina; T S Zatsepin; Yu Yu Agapkina; M G Isaguliants; M B Gottikh
Journal:  Acta Naturae       Date:  2015 Jan-Mar       Impact factor: 1.845

10.  Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.

Authors:  Xue Zhi Zhao; Steven J Smith; Mathieu Métifiot; Barry C Johnson; Christophe Marchand; Yves Pommier; Stephen H Hughes; Terrence R Burke
Journal:  J Med Chem       Date:  2014-02-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.